Sanesco International

Executive Summary

Sanesco International is a privately held US company specializing in neuroendocrine health diagnostics and personalized wellness solutions. Founded in 2004 and headquartered in Asheville, North Carolina, the company provides clinical tools, including neurotransmitter and hormone testing, to help healthcare providers assess and manage the hypothalamic-pituitary-adrenal (HPA) axis and related symptoms. Its flagship NeuroWellness Program offers a comprehensive approach to support personalized treatment plans for patients with neuroendocrine imbalances. Operating at the intersection of neuroscience and metabolic health, Sanesco serves a growing market demand for integrative and functional medicine solutions. Despite being a private entity with limited public financial disclosures, the company has established a niche in the expanding field of personalized medicine and diagnostics. Its focus on the HPA axis aligns with rising interest in stress-related disorders, chronic fatigue, and metabolic syndrome, positioning it for potential growth as awareness of neuroendocrine health increases among both clinicians and patients.

Upcoming Catalysts (preview)

• Q3 2026Launch of New Comprehensive Neurotransmitter Panel70% success
• Q4 2026Strategic Partnership with Major Functional Medicine Network50% success
• Q1 2027FDA Clearance for a Novel HPA Axis Diagnostic Test30% success